Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
48 Results for "
ArlS
" in MedChemExpress (MCE) Product Catalog:
Products (48)
48 Results for "ArlS" in MCE Product Catalog:
4
4 Cited Publications
Synonyms: FPL 67156 trisodium
Target:
Research Areas:
ARL67156 (FPL 67156) trisodium is a selective small molecular inhibitor, targeting to ecto-ATPase, CD39, and CD73. ARL67156 trisodium is also a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with Kis of 11, 18 and 12?μM, respectively. ARL67156 trisodium can be used in the research of calcific aortic valve disease, asthma .
4
Target:
Research Areas:
ARL67156 (FPL 67156) triethylamine is a selective small is a selective samll molecular inhibitor, targeting to ecto-ATPase, CD39, and CD73. ARL67156 triethylamine is also a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with Kis of 11, 18 and 12 μM, respectively. ARL67156 triethylamine can be used in the research of disease like calcific aortic valve disease, asthma .
3
Target:
Research Areas:
Oritavancin diphosphate (LY333328 diphosphate), a semisynthetic derivative of Vancomycin (HY-B0671), is an orally active glycopeptide antibiotic with bactericidal activity against gram-positive organisms. Oritavancin diphosphate shows antibacterial effect against B. anthracis, such as Ames strain with a MIC value of 0.015 g/mL. Oritavancin diphosphate inhibits cell wall synthesis and disrupts the membrane potential. Oritavancin diphosphate inhibits ArlS kinase activity thereby interfering the signal transduction. Oritavancin diphosphate enters cells by adsorptive endocytosis, which drives it to lysosomes, where it exerts antibiotic activity .
1
1 Cited Publications
Target:
ARL 17477 is a blood-brain barrier-penetrant selective neuronal nitric oxide synthase (nNOS) inhibitor with an IC50 of 1 μM. ARL 17477 reduces nitric oxide production and activates TFEB and lysosomal biogenesis, induces lysosomal membrane permeabilization, but inhibits autophagy-lysosomal function, autophagic flux, protein aggregate clearance, and proliferation. ARL 17477 induces ERK hyperphosphorylation and slight AKT inhibition. ARL 17477 exhibits NOS1 -independent anticancer activity against multiple cancer cells. ARL 17477 inhibits xenograft tumor growth in vivo. ARL 17477 can be used in research on colon cancer, non-small cell lung cancer, osteosarcoma, pancreatic cancer, arterial occlusion, and pain .
Cat. No.: HY-103265B
Purity: 99.94%
Synonyms: FPL 67156 trisodium hydrate
Target:
Research Areas:
ARL67156 (FPL 67156) trisodium hydrate is a selective small is a selective samll molecular inhibitor, targeting to ecto-ATPase, CD39, and CD73. ARL67156 trisodium hydrate is also a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with Kis of 11, 18 and 12 μM, respectively. ARL67156 trisodium hydrate can be used in the research of disease like calcific aortic valve disease, asthma .
Cat. No.: HY-RS00985
Target:
Research Areas:
ARL2 Human Pre-designed siRNA Set A contains three designed siRNAs for ARL2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-B1831
CAS No.: 171099-57-3
Synonyms: LY 333328; Orbactiv
Target:
Research Areas:
Oritavancin (LY 333328), a semisynthetic derivative of Vancomycin (HY-B0671), is an orally active glycopeptide antibiotic with bactericidal activity against gram-positive organisms. Oritavancin shows antibacterial effect against B. anthracis, such as Ames strain with a MIC value of 0.015 g/mL. Oritavancin inhibits cell wall synthesis and disrupts the membrane potential. Oritavancin inhibits ArlS kinase activity thereby interfering the signal transduction. Oritavancin enters cells by adsorptive endocytosis, which drives it to lysosomes, where it exerts antibiotic activity .
Cat. No.: HY-103265A
CAS No.: 160928-38-1
Synonyms: FPL 67156
Target:
Research Areas:
ARL67156 is an inhibitor of ecto-ATPase. ARL 67156 is a weak competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with Kis of 11, 18 and 12 μM, respectively .
Cat. No.: HY-RS00977
Target:
Research Areas:
ARL1 Human Pre-designed siRNA Set A contains three designed siRNAs for ARL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS00978
Target:
Research Areas:
ARL10 Human Pre-designed siRNA Set A contains three designed siRNAs for ARL10 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS00979
Target:
Research Areas:
ARL11 Human Pre-designed siRNA Set A contains three designed siRNAs for ARL11 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS00981
Target:
Research Areas:
ARL14 Human Pre-designed siRNA Set A contains three designed siRNAs for ARL14 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS00983
Target:
Research Areas:
ARL15 Human Pre-designed siRNA Set A contains three designed siRNAs for ARL15 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS00984
Target:
Research Areas:
ARL16 Human Pre-designed siRNA Set A contains three designed siRNAs for ARL16 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS00987
Target:
Research Areas:
ARL3 Human Pre-designed siRNA Set A contains three designed siRNAs for ARL3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS00988
Target:
Research Areas:
ARL4A Human Pre-designed siRNA Set A contains three designed siRNAs for ARL4A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS00991
Target:
Research Areas:
ARL5A Human Pre-designed siRNA Set A contains three designed siRNAs for ARL5A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS00993
Target:
Research Areas:
ARL6 Human Pre-designed siRNA Set A contains three designed siRNAs for ARL6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS00998
Target:
Research Areas:
ARL8A Human Pre-designed siRNA Set A contains three designed siRNAs for ARL8A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS01000
Target:
Research Areas:
ARL9 Human Pre-designed siRNA Set A contains three designed siRNAs for ARL9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
